• Shopping cart is empty.

    The International Society for Aerosols in Medicine

    Anh Tuan Dinh-Xuan

    Anh Tuan Dinh-Xuan

    Dr. Anh Tuan Dinh-Xuan

    Respiratory Physiology Unit, Cardiothoracic Department.
    Paris Descartes University, Cochin Hospital, France

    Anh Tuan Dinh-Xuan has got his MD from Paris Descartes University (France) and his PhD in Clinical Sciences from the University of Cambridge (UK). He is currently the Head of the Clinical Physiology Unit of the Thoracic Department of Cochin Hospital - Paris Descartes University, France. His research is focused on the role of nitric oxide in respiratory physiology and pulmonary diseases.

    Pulmonary Hypertension: Background and Unmet Needs


    The field of pulmonary hypertension is large and encompasses a broad range of diseases and conditions affecting hundreds of thousands of patients worldwide [1]. For a single but rather rare form of pulmonary hypertension, called pulmonary arterial hypertension (PAH), several classes of drugs are now available. These drugs have a substantial impact on the survival of patients with PAH. For instance, 3-yr survival rates have increased from approximately 40% in the 1980s [2] to nearly 80% in current case series [3–5]. One of the most significant breakthroughs at the turn of this century was the discovery of the role played by bone morphogenetic protein receptor type II (BMPR-II) gene in the pathophysiology of familial pulmonary hypertension [6, 7]. This led to a revival of interest in the use of genetic studies to dissect mechanisms and pathways leading to pulmonary vascular disease [8]. However, it soon became clear that the discovery of genes involved in disease would be of little help if the signalling pathways that are perturbed as a result of gene mutation could not be delineated. Furthermore, considering the variety of different types of pulmonary hypertension, it is probable that several factors are likely to be involved in this complex and intricate biological puzzle [9, 10]. Although understanding the cause of severe pulmonary hypertension is crucial, it is certainly not the ultimate target. The main concern remains how to detect the disease in its early development and how to cure patients of this dreadful condition. 


    1. Humbert M. The burden of pulmonary hypertension. Eur Respir J 2007; 30: 1–2.
    2. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343–349.
    3. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral Bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60: 1025–1030.
    4. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858–863.